What is Bioxyne’s New Partnership About?

Bioxyne’s Latest Update

Bioxyne Limited (AU:BXN) has recently announced a significant update.

New Partnership with Cy Biopharma AG

Bioxyne Limited has expanded its pharmaceutical reach by partnering with Cy Biopharma AG. This collaboration aims to manufacture and supply Psilocybin products for clinical trials and authorized prescriber schemes across Australia, New Zealand, the US, and Europe.

What Does the Partnership Include?

The partnership includes the development of proprietary formulations and a profit-sharing agreement for the sale of starting materials. Although the financial impact is not yet quantified, this agreement is a strategic move in Bioxyne’s multinational operations in health and wellness products.

Want to Know More?

For further insights into AU:BXN stock, check out TipRanks’ Stock Analysis page.